IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-33599-w.html
   My bibliography  Save this article

Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

Author

Listed:
  • Edward M. Kennedy

    (Oncorus, Inc.)

  • Agnieszka Denslow

    (Oncorus, Inc.)

  • Jacqueline Hewett

    (Oncorus, Inc.)

  • Lingxin Kong

    (Oncorus, Inc.)

  • Ana Almeida

    (Oncorus, Inc.)

  • Jeffrey D. Bryant

    (Oncorus, Inc.)

  • Jennifer S. Lee

    (Oncorus, Inc.)

  • Judy Jacques

    (Oncorus, Inc.)

  • Sonia Feau

    (Oncorus, Inc.)

  • Melissa Hayes

    (Oncorus, Inc.)

  • Elizabeth L. McMichael

    (Oncorus, Inc.)

  • Daniel Wambua

    (Oncorus, Inc.)

  • Terry Farkaly

    (Oncorus, Inc.)

  • Amal A Rahmeh

    (Oncorus, Inc.)

  • Lauren Herschelman

    (Oncorus, Inc.)

  • Danielle Douglas

    (Oncorus, Inc.)

  • Jacob Spinale

    (Oncorus, Inc.)

  • Sanmit Adhikari

    (Oncorus, Inc.)

  • Jessica Deterling

    (Oncorus, Inc.)

  • Matt Scott

    (Oncorus, Inc.)

  • Brian B. Haines

    (Oncorus, Inc.)

  • Mitchell H. Finer

    (Oncorus, Inc.)

  • Ted T Ashburn

    (Oncorus, Inc.)

  • Christophe Quéva

    (Oncorus, Inc.)

  • Lorena Lerner

    (Oncorus, Inc.)

Abstract

The therapeutic effectiveness of oncolytic viruses (OVs) delivered intravenously is limited by the development of neutralizing antibody responses against the virus. To circumvent this limitation and to enable repeated systemic administration of OVs, here we develop Synthetic RNA viruses consisting of a viral RNA genome (vRNA) formulated within lipid nanoparticles. For two Synthetic RNA virus drug candidates, Seneca Valley virus (SVV) and Coxsackievirus A21, we demonstrate vRNA delivery and replication, virus assembly, spread and lysis of tumor cells leading to potent anti-tumor efficacy, even in the presence of OV neutralizing antibodies in the bloodstream. Synthetic-SVV replication in tumors promotes immune cell infiltration, remodeling of the tumor microenvironment, and enhances the activity of anti-PD-1 checkpoint inhibitor. In mouse and non-human primates, Synthetic-SVV is well tolerated reaching exposure well above the requirement for anti-tumor activity. Altogether, the Synthetic RNA virus platform provides an approach that enables repeat intravenous administration of viral immunotherapy.

Suggested Citation

  • Edward M. Kennedy & Agnieszka Denslow & Jacqueline Hewett & Lingxin Kong & Ana Almeida & Jeffrey D. Bryant & Jennifer S. Lee & Judy Jacques & Sonia Feau & Melissa Hayes & Elizabeth L. McMichael & Dani, 2022. "Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33599-w
    DOI: 10.1038/s41467-022-33599-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-33599-w
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-33599-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33599-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.